Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları

CÖNGÖLOĞLU, MEHMET AYHAN; Bilgiç, Ayhan

Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları

Ayhan BİLGİÇ, (GATA Çocuk Ruh Sağlığı ve Hastalıkları Anabilim Dalı, Ankara, Türkiye)

MEHMET AYHAN CÖNGÖLOĞLU (GATA Çocuk Ruh Sağlığı ve Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Çocuk ve Gençlik Ruh Sağlığı Dergisi

25 2

Yıl: 2009 Cilt: 16 Sayı: 3 Sayfa Aralığı: 153 - 164 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları

Öz:

Amaç: Otizm spektrum bozukluğu (OSB) tanısı konulan çocukların oranında gözlenen artışa paralel olarak OSB’nin tedavisi üzerine olan ilgi de artmaktadır. OSB’de etiyolojiyi temel alan bir tedavi yönteminin henüz olmaması, olası bir tedavi amacıyla tamamlayıcı ve alternatif tıp (TAT) uygulamalarının kullanılmasına yol açmaktadır. Bu makalede, biyolojik temele dayandırılarak yapılan TAT uygulamaları ile ilgili bir gözden geçirme yapılmıştır. Yöntem: OSB’de uygulanmakta olan TAT uygulamalarını inceleyen yayınlar Pubmed (Medline) arama motoru üzerinden taranmış, biyolojik temele dayandırılarak yapılan TAT uygulamaları ile ilgili veri içeren toplam 78 makaleden yararlanılmıştır. Sonuçlar: OSB’li bireylerde TAT uygulamalarını kullanım oranları batı ülkelerinde %92’lere dek ulaşmaktadır. Tedavi amacıyla şelasyon tedavisi, hiperbarik oksijen tedavisi, gluten ve kazeinden yoksun gıdaların tüketilmesi, ek vitamin ve mineral kullanımı, antifungal ve antiviral ilaçlar, intravenöz immünglobulin (IVIG) ve sekretin uygulamaları gibi birçok yönteme başvurulduğu görülmektedir. Bununla birlikte, aşıların otizme neden olduğu varsayımı ve sekretin kullanımı dışındaki varsayım ve uygulamaların yeterince araştırılmadığı gözlenmiştir. Tartışma: TAT uygulamaları fiziksel sağlık üzerine zararlı olabilmekte ve ailelere duygusal ve ekonomik bakımdan ek yükler getirmektedir. Klinisyenlerin anne babaları bu uygulamalar ve onların potansiyel riskleri konusunda bilgilendirmesi gerekli olabilir. Sıklıkla güncel nörobilim algılamamızla uyumlu olmasalar da, bu uygulamaların yöntemsel olarak güçlü çalışmalar zemininde incelenmeleri gerekmektedir.

Anahtar Kelime:

Konular: Psikoloji

The biologically based complementary and alternative treatments in autism spectrum disorders

Öz:

Objective: The increase in the rate of children with autism spectrum disorder (ASD) induced a parallel interest in treatments for children with ASD. The lack of treatment methods which are focused on etiologic origins in ASD brought about use of complementary and alternative medicine assuming as a possi- ble treatment. In this article, we reviewed the biologically based complementary and alternative medicine (CAM) applications in ASD. Method: We searched for the articles related to the CAM applications in ASD through Pubmed (Medline) and we benefited from 78 articles including the data about biologically based CAM in ASD. Results: The rate of CAM use in ASD reached to a level as high as 92% in western countries. It has been observed that a multitude of various methods, including chelating agents, hyperbaric oxygen treatment, intake of gluten and casein-free diet, vitamin and mineral supplementations, antifungal and antiviral agents, IVIG and secretin administration, have been used to treat ASD. However, these issues had not been investigated enough except the association between ASD and vaccines and secretin. Discussion: The CAM applications may cause harm on physical health and they bring extra emotional and economic burden to the family. It might be necessary for clinicians to inform parents about these applications and their possible potential risks. To clarify the efficacy of the CAM approaches, it is necessary to investigate these methods by the studies conducted with sound methodology, although these applications are often not compatible with our current scientific understanding of neuroscience.

Anahtar Kelime:

Konular: Psikoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Adams JB, Romdalvik J, Ramanujam VM ve ark. (2007) Mercury, lead, and zinc in baby teeth of children with autism versus controls. J Toxicol and Environ Health A 70: 1046-1051
Adams JB, Holloway C (2004) Pilot study of a moderate dose mul- tivitamin/mineral supplement for children with autistic spectrum disorder. J Altern Complement Med 10: 1033-1039
Afzal MA, Ozoemena LC, O’Hare A ve ark. (2006) Absence of detectable measles virus genome sequence in blood of autism child- ren who have had their MMR vaccination during the routine child- hood immunization schedule of UK. J Med Virol 78:623-630.
Ahearn GA, Mandal PK, Mandal A (2004) Mechanisms of heavy metal sequestration and detoxiﬁcation in crustaceans: a review. J Comp Physiol B 174:439-452.
Alberti A, Pirrone P, Elia M ve ark. (1999) Sulphation deﬁcit in “low-functioning” autistic children: a pilot study. Biol Psychiatry 46:420-424.
Al-Waili NS, Butler GJ (2006) Effects of hyperbaric oxygen on inﬂammatory response to wound and trauma: possible mechanism of action. Scientiﬁc World Journal 6:425-441.
Amminger GP, Berger GE, Schafer MR ve ark (2007) Omega-3 fatty acids supplementation in children with autism: a double- blind randomized, placebo-controlled pilot study. Biol Psychiatry 61:551-553.
Andrews N, Miller E, Grant A ve ark. (2004) Thimerosal exposu- re in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal associati- on. Pediatrics 114:584-591
Baird G, Pickles A, Simonoff E ve ark. (2008) Measles vaccination and antibody response in autism spectrum disorders Arch Dis Child 93:832-837
Bernard S, Enayati A, Redwood L ve ark. (2001) Autism: a novel form of mercury poisoning. Med Hypotheses 56:462-471
Boddaert N, Zilbovicius M (2002) Functional neuroimaging and childhood autism. Pediatr Radiol 32(1):1-7.
Brown MJ, Willis T, Omalu B ve ark. (2006). Deaths resulting from hypocalcemia after administration of edetate disodium: 2003- 2005. Pediatrics 118: 534-536
Buchman AL, Fife C, Torres C ve ark. (2001) Hyperbaric oxygen therapy for severe ulcerative colitis. J Clin Gastroenterol 33:337- 339.
Chakrabarti S, Fombonne E (2005) Pervasive developmental disor- ders in preschool children: conﬁrmation of high prevalence. Am J Psychiatry 162:1133-1141
Christison GW, Ivany K (2006) Elimination diets in autism spect- rum disorders: any wheat amidst the chaff? J Dev Behav Pediatr 27:S162-171
Chungpaibulpatana J, Sumpatanarax T, Thadakul N ve ark. (2008) Hyperbaric oxygen therapy in Thai autistic children. J Med Assoc Thai 91:1232-1238
Collet JP, Vanasse M, Marois P ve ark. (2001) Hyperbaric oxygen for children with cerebral palsy: a randomised multicentre trial. HBO-CP Research Group. Lancet 357:582-586.
Danfors T, von Knorring AL, Hartvig P ve ark. (2005) Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. J Clin Psychopharmacol 25:485-489
DelGuidice-Asch G, Simon L, Schmeidler J ve ark. (1999). Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord 29:157-160.
Dietrich KN, Ware JH, Salganik M ve ark. (2004) Effect of chela- tion therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics 114:19-26.
Dolske MC, Spollen J, McKay S ve ark. (1993). A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry 17:765-774.
Doğan A (1996) Solunum sisteminin yapısal özellikleri, Temel İç Hastalıkları içinde, İliçin G, Ünal S, Biberoğlu K, Akalın S, Süleymanlar G (ed) Güneş Kitabevi, Ankara, s:405-410
D’Souza Y, Fombonne E, Ward BJ (2006) No evidence of persisting measles virus in peripheral blood mononuclear cells from children with autism spectrum disorder. Pediatrics 118:1664-1675.
Elder JH, Shankar M, Shuster J ve ark. (2006) The gluten-free, casein-free diet in autism: results of a preliminary double blind cli- nical trial. J Autism Dev Disord 36:413-420
Esch BE, Carr JE (2004) Secretin as a treatment for autism: a revi- ew of the evidence. Journal of Autism and Developmental Disorders, 34:543-556
Fernell E, Watanabe Y, Adolfsson I ve ark.(1997) Possible effects of tetrahydrobiopterin treatment in six children with autism—clini- cal and positron emission tomography data: a pilot study. Dev Med Child Neurol. 39:313-318.
Fido A, Al-Saad S (2005) Toxic trace elements in the hair of child- ren with autism. Autism 9:290-298
Findling RL, Maxwel K, Scotese-Wojtila L ve ark. (1997) High- dose pyridoxine and magnesium administration in children with autistic disorder: An absence of salutary effects in a double-blind, placebo-controlled study. J Autism Dev Disord 27:467-478.
Fombonne E, Zakarian R, Bennett A ve ark (2006) Pervasive deve- lopmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 118;139-150.
Furlano RI, Anthony A, Day R ve ark. (2001) Colonic CD8 and gamma delta T-cell inﬁltration with epithelial damage in children with autism. J Pediatr 138:366-372.
Geier MR, Geier DA (2003)a Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication. Exp Biol Med 228:660-664.
Geier DA, Geier MR (2003)b Thimerosal in childhood vaccines, neurodevelopmental disorders, and heart disease in the United States. J Am Phys Surg 8:6-11
Geier DA, Geier MR (2003)c An assessment of the impact of thi- merosal on childhood neurodevelopmental disorders. Pediatr Rehabil 6:97-102.
Geier DA, Geier MR (2004) A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-contai- ning childhood vaccines on the population prevalence of autism. Med Sci Monit 10:133-139.
Geier DA, Geier MR (2006) A clinical trial of combined anti- androgen and anti-heavy metal therapy in autistic disorders. Neuro Endocrinol Lett 27:833-838.
Geier DA, King PG, Sykes LK ve ark. (2008) A comprehensive review of mercury provoked autism. Indian J Med Res 128:383- 411.
Geier DA, Kern JK, Garver CR ve ark. (2009)a Biomarkers of envi- ronmental toxicity and susceptibility in autism. J Neurol Sci 280: 101-108.
Geier DA, Kern JK, Garver CR ve ark. (2009)b A prospective study of transsulfuration biomarkers in autistic disorders. Neurochem Res 34:386-393.
Grandjean P, Weihe P, Nielsen JB (1994) Methylmercury: Signiﬁcance of intrauterine and postnatal exposures. Clin Chem 40:1395-1400.
Grether JK, Croen L, Theis C ve ark. (2004) Baby hair, mercury toxicity and autism. Int J Toxicol 23:275-276.
Gupta S, Aggarwal S, Heads C (1996) Dysregulated immune system in children with autism: beneﬁcial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord 26:439-452.
Harrington JW, Rosen L, Garnecho A ve ark. (2006) Parental per- ceptions and use of complementary and alternative medicine prac- tices for children with autistic spectrum disorders in private prac- tice. J Dev Behav Pediatr 27:S156-161.
Heron J, Golding J; ALSPAC Study Team (2004) Thimerosal expo- sure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not support a causal associati- on. Pediatrics.114:577-583.
Holmes AS, Blaxill MF, Haley BE (2003) Reduced levels of mer- cury in ﬁrst baby haircuts of autistic children. Int J Toxicol 22:277- 285.
Horvath K, Stefanatos G, Sokolski KN ve ark. (1998) Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys 9: 9- 15.
Hviid A, Stellfeld M, Wohlfahrt J ve ark. (2003). Association bet- ween thimerosal-containing vaccine and autism. JAMA. 290:1763-1766.
Ip P, Wong V, Ho M ve ark. (2004) Mercury exposure in children with autistic spectrum disorder: case-control study. J Child Neurol 19:431-434.
James SJ, Cutler P, Melnyk S ve ark. (2004). Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 80:1611-1617.
James SJ, Rose S, Melnyk S ve ark. (2009) Cellular and mitochon- drial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. Faseb J 23:2374-2383.
Kawashima H, Mori T, Kashiwagi Y ve ark. (2000) Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inﬂammatory bowel disease and autism. Dig Dis Sci 45:723-729.
Kern JK, Miller VS, Evans PA ve ark.(2002) Efﬁcacy of porcine secretin in children with autism and pervasive developmental disorder. J Autism Dev Disord 32:153-160.
Knivsberg A, Reichelt KL, Hoien T ve ark. (2002) A randomized, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci 5:251-261.
Komori H, Matsuishi T, Yamada S ve ark. (1995). Cerebrospinal ﬂuid biopterin and biogenic amine metabolites during oral R- THBP therapy for infantile autism. J Autism Dev Disord 25:183- 193.
Levy SE, Hyman SL (2005). Novel treatments for autistic spect- rum disorders. Ment Retard Dev Disabil Res Rev 11:131-142.
Madsen KM, Lauritsen MB, Pedersen CB ve ark (2003)
Thimerosal and the occurrence of autism: negative ecological evi- dence from Danish population based data. Pediatrics 112:604-606.
Martineau J, Barthelemy C, Cheliakine C ve ark. (1988) Brief report: an open middle-term study of combined vitamin B6-magne- sium in a subgroup of autistic children selected on their sensitivity to this treatment. J Autism Dev Disord 18:435-447.
Millward C, Ferriter M, Calver S ve ark. (2008). Gluten- and case- in-free diets for autistic spectrum disorder. Cochrane Database Syst Rev 16;(2): CD003498
Nye C, Brice A( 2005). Combined vitamin B6-magnesium treat- ment in autism spectrum disorder. Cochrane Database Syst Rev 19;(4):CD003497
Nelson KB, Bauman ML (2003) Thimerosal and autism? Pediatrics 111;674-679.
Panksepp J (1979). A neurochemical theory of autism. Trends Neurosci. 2:174-177
Pardo CA, Vargas DL, Zimmerman AW (2005) Immunity, neu- roglia and neuroinﬂammation in autism. Int Rev Psychiatry 17:485-495.
Parker SK, Schwartz B, Todd J ve ark. (2004). Thimerosal-contai- ning vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics 114:793-804.
Pliopys AV (1998). Intravenous immunoglobulin treatment of children with autism. J Child Neurol 13:79-82.
Politi P, Cena H, Comelli M ve ark (2008). Behavioral effects of omega-3 fatty acid supplementation in young adults with severe autism: an open label study. Arch Med Res 39:682-685.
Prudova A, Albin M, Bauman Z ve ark. (2007) Testosterone regu- lation of homocysteine metabolism modulates redox status in human prostate cancer cells. Antioxid Redox Signal 9:1875-81.
Richardson AJ, Montgomery P (2005): The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disor- der. Pediatrics 115:1360-1366.
Rossignol DA (2007) Hyperbaric oxygen therapy might improve certain pathophysiological ﬁndings in autism. Med Hypotheses 68:1208-1227.
Rossignol DA, Rossignol LW, James SJ ve ark. (2007) The effects of hyperbaric oxygen therapy on oxidative stress, inﬂammation, and symptoms in children with autism: an open-label pilot study. BMC Pediatr 7:36.
Rossignol DA, Rossignol LW, Smith S ve ark. (2009) Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatrics 9:21..
Rowland IR, Robinson RD, Doherty RA (1984). Effect of diet on mercury metabolism and excretion in mice given methylmercury: role of gut ﬂora. Arch Environ Health 39:401-408.
Sandler AD, Sutton KA, DeWeese J ve ark. (1999) Lack of beneﬁt of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Eng J Med 341:1801-1806
Schechter R, Grether JK (2008) Continuing increase in autism reported to California’s developmental services system: mercury in retrograde. Arch Gen Psychiatry 65:19-24.
Singh VK, Jensen RL (2003) Elevated levels of measles antibodies in children with autism. Pediatr Neurol 28:292-294.
Smith MJ, Ellenberg SS, Bell LM ve ark. (2008) Media coverage of the measles-mumps-rubella vaccine and autism controversy and its relationship to MMR immunization rates in the United States. Pediatrics 121:e836-e843.
Soden SE, Lowry JA, Garrison JB ve ark. (2007) 24-hour provoked urine excretion test for heavy metals in children with autism and typically developing controls, a pilot study. Clin Toxicol (Phila) 45:476-481.
Stehr-Green P, Tull P, Stellfeld M ve ark.(2003) Autism and thime- rosal-containing vaccines: lack of consistent evidence for an asso- ciation. Am J Prev Med 25:101-106.
Sturmey P (2005) Secretin is an ineffective treatment for pervasi- ve developmental disabilities: a review of 15 double-blind randomi- zed controlled trials. Res Dev Disabil 26: 87-97.
Takeshima F, Makiyama K, Doi T (1999) Hyperbaric oxygen as adjunct therapy for Crohn's intractable enteric ulcer. Am J Gastroenterol 94:3374-3375.
Taylor B, Miller E, Lingram L ve ark. (2002) Measles, mumps, and rubella vaccination and bowel problems or developmental regressi- on in children with autism: population study. BMJ 324: 393-396.
Thomas DJ, Fisher HL, Sumler MR ve ark. (1987) Sexual differen- ces in the excretion of organic and inorganic mercury by methyl mercury-treated rats. Environ Res 43:203-16.
Tolbert L, Haigler T, Waits MM, Dennis T (1993) Brief report: lack of response in an autistic population to a low dose clinical trial of pyridoxine plus magnesium. J Autism Dev Disord 23:193-199.
Uchiyama T, Kurosawa M, Inaba Y (2007) MMR-Vaccine and reg- ression in autism spectrum disorders: negative results presented from Japan. J Autism Dev Disord 37:210-217
Uhlmann V, Martin CM, Sheils O ve ark (2002) Potential viral pathogenic mechanism for new variant inﬂammatory bowel disea- se. Mol Pathol 55:84-90.
Vargas DL, Nascimbene C, Krishnan C ve ark. (2005) Neuroglial activation and neuroinﬂammation in the brain of patients with autism. Ann Neurol 57:67-81.
Vancassel S, Durand G, Barthelemy C ve ark. (2001): Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids 65:1-7.
Verstraeten T, Davis RL, DeStefano F ve ark. (2003). Safety of thi- merosal containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics 112:1039- 1048.
Wakeﬁeld AJ, Murch SH, Anthony A ve ark. (1998) Ileal-lympho- id-nodular hyperplasia, non-speciﬁc colitis, and pervasive develop- mental disorder in children. Lancet 351:637-641.
Williams JG, Higgins JP, Brayne CE (2006) Systematic review of prevalence studies of autism spectrum disorders. Arch Dis Child 91:8-15.
Williams E, Thomas K, Sidebotham H ve ark. (2008) Prevalence and characteristics of autistic spectrum disorders in the ALSPAC cohort. Dev Med Child Neurol 50:672-677
Young HA, Geier DA, Geier MR (2008) Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of com- puterized medical records in the Vaccine Safety Datalink. J Neurol Sci 271:110-118.
Zilbovicius M, Boddaert N, Belin P ve ark. (2000) Temporal lobe dysfunction in childhood autism: a PET study. Positron emission tomography. Am J Psychiatry 157:1988-1993.

APA	Bilgiç A, CÖNGÖLOĞLU M (2009). Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları. , 153 - 164.
Chicago	Bilgiç Ayhan,CÖNGÖLOĞLU MEHMET AYHAN Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları. (2009): 153 - 164.
MLA	Bilgiç Ayhan,CÖNGÖLOĞLU MEHMET AYHAN Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları. , 2009, ss.153 - 164.
AMA	Bilgiç A,CÖNGÖLOĞLU M Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları. . 2009; 153 - 164.
Vancouver	Bilgiç A,CÖNGÖLOĞLU M Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları. . 2009; 153 - 164.
IEEE	Bilgiç A,CÖNGÖLOĞLU M "Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları." , ss.153 - 164, 2009.
ISNAD	Bilgiç, Ayhan - CÖNGÖLOĞLU, MEHMET AYHAN. "Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları". (2009), 153-164.

APA	Bilgiç A, CÖNGÖLOĞLU M (2009). Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları. Çocuk ve Gençlik Ruh Sağlığı Dergisi, 16(3), 153 - 164.
Chicago	Bilgiç Ayhan,CÖNGÖLOĞLU MEHMET AYHAN Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları. Çocuk ve Gençlik Ruh Sağlığı Dergisi 16, no.3 (2009): 153 - 164.
MLA	Bilgiç Ayhan,CÖNGÖLOĞLU MEHMET AYHAN Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları. Çocuk ve Gençlik Ruh Sağlığı Dergisi, vol.16, no.3, 2009, ss.153 - 164.
AMA	Bilgiç A,CÖNGÖLOĞLU M Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları. Çocuk ve Gençlik Ruh Sağlığı Dergisi. 2009; 16(3): 153 - 164.
Vancouver	Bilgiç A,CÖNGÖLOĞLU M Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları. Çocuk ve Gençlik Ruh Sağlığı Dergisi. 2009; 16(3): 153 - 164.
IEEE	Bilgiç A,CÖNGÖLOĞLU M "Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları." Çocuk ve Gençlik Ruh Sağlığı Dergisi, 16, ss.153 - 164, 2009.
ISNAD	Bilgiç, Ayhan - CÖNGÖLOĞLU, MEHMET AYHAN. "Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları". Çocuk ve Gençlik Ruh Sağlığı Dergisi 16/3 (2009), 153-164.